HKEX is one of the world’s major exchange groups, and operates a range of equity, commodity, fixed income and currency markets.

See below for the Latest HKEX News, Analysis, Profit Results, Share Price Information, and Commentary.

HK’s IPO market sees slowdown in H122

Funds raised in H122 plummeted by 92% YoY. 
in 2 days

HK’s IPO market sees slowdown in H122

Funds raised in H122 plummeted by 92% YoY. 
in 2 days

After 25 years, has Hong Kong’s capital markets lost its sparkle?

Funds raised by IPOs in H122 are predicted to reach HK$17.1 b, a 92% decrease from 2021.

HKEX lists first MSCI China A 50 Connect Index ETFs

A total of three EFTs listed on the bourse.

HKEX mulls establishment of New York office

The office is expected to open as early as 2022.

HKEX profit declines anew, falling ​​to HK$3.3 billion in Q3

The bourse’s income was dragged down by the delay in potential billion-dollar IPOs.

HKEX enters China's derivatives market with A-share futures launch

The bourse’s new futures contract is based on the MSCI China A 50 Connect Index.

How HKEX's A-share futures launch will shake up Singapore’s monopoly in China

SGX shares already slumped 4% when HK announced the futures’ launch on 23 August.

HK cancels Wednesday stock trading due to Typhoon Kompasu

The Hong Kong-China stock connect and derivatives markets were also halted.

HKEX proposes prudent approach on SPAC listings

The public consultation will end on 31 October.

China and HK IPO market forecast in Q4 positive: Deloitte

HK remains a preferred overseas listing destination for Chinese companies.

HKEX raises the bar on profit requirements

The regulatory body also plans to keep a watchful eye on IPO-related malpractices.

HKEX appoints new Chief Compliance Officer

Adam Singer will join the company in September.

The Exchange, FRC strengthen financial reports oversight

This is to ensure the quality of financial reports of listed companies is upheld.

HKEX employees get 2-day vaccine leave

This is in line with the Hong Kong’s vaccine drive.